Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$1.48 +7.2%	$1.14	$0.86 ▼ $3.60	$89.65M	0.11	295,983 shs	675,856 shs
ARCT Arcturus Therapeutics	$13.54 +5.4%	$12.74	$8.04 ▼ $25.88	$367.22M	2.27	416,793 shs	397,041 shs
BNTC Benitec Biopharma	$11.74 -0.1%	$14.10	$7.05 ▼ $17.15	$308.18M	0.37	58,391 shs	147,943 shs
GOSS Gossamer Bio	$1.71 +3.0%	$1.26	$0.66 ▼ $1.79	$388.68M	1.86	1.47 million shs	6.19 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	+5.34%	+10.40%	+21.05%	+53.20%	-56.19%
ARCT Arcturus Therapeutics	-2.28%	-13.12%	-0.16%	+22.03%	-49.37%
BNTC Benitec Biopharma	-5.55%	-15.10%	-25.40%	-14.55%	+12.87%
GOSS Gossamer Bio	+14.48%	+22.06%	+29.69%	+97.62%	+32.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABOS Acumen Pharmaceuticals	2.8678 of 5 stars	3.5	4.0	0.0	1.9	1.7	0.6
ARCT Arcturus Therapeutics	1.9508 of 5 stars	3.6	0.0	0.0	1.9	2.5	0.6
BNTC Benitec Biopharma	1.6135 of 5 stars	3.6	1.0	0.0	2.5	0.8	0.0
GOSS Gossamer Bio	3.7876 of 5 stars	3.5	1.0	4.7	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	3.00	Buy	$6.33	327.93% Upside
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	298.82% Upside
BNTC Benitec Biopharma	3.20	Buy	$23.83	103.01% Upside
GOSS Gossamer Bio	3.00	Buy	$8.25	382.46% Upside

Current Analyst Ratings Breakdown

Latest ABOS, ARCT, BNTC, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/17/2025	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$3.03 per share	N/A
ARCT Arcturus Therapeutics	$131.27M	2.80	N/A	N/A	$8.90 per share	1.52
BNTC Benitec Biopharma	$80K	3,852.19	N/A	N/A	$4.68 per share	2.51
GOSS Gossamer Bio	$114.70M	3.39	N/A	N/A	$0.13 per share	13.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$102.33M	-$1.94	N/A	N/A	N/A	N/A	-58.24%	-46.53%	8/12/2025 (Estimated)
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)

Latest ABOS, ARCT, BNTC, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ABOS Acumen Pharmaceuticals	-$0.54	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
8/4/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	N/A	N/A	N/A	$17.64 million	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/13/2025	Q1 2025	ABOS Acumen Pharmaceuticals	-$0.56	-$0.48	+$0.08	-$0.48	N/A	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$0.71	5.28%	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.19	8.02	8.02
ARCT Arcturus Therapeutics	0.06	5.64	5.64
BNTC Benitec Biopharma	0.01	14.80	14.80
GOSS Gossamer Bio	6.70	5.71	5.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
ARCT Arcturus Therapeutics	94.54%
BNTC Benitec Biopharma	52.19%
GOSS Gossamer Bio	81.23%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	9.30%
ARCT Arcturus Therapeutics	16.60%
BNTC Benitec Biopharma	1.30%
GOSS Gossamer Bio	6.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	60.57 million	54.94 million	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable

ABOS, ARCT, BNTC, and GOSS Headlines

Recent News About These Companies

Gossamer Bio (NASDAQ:GOSS) Coverage Initiated at Scotiabank

July 16 at 4:09 AM | americanbankingnews.com

Scotiabank Initiates Coverage of Gossamer Bio (GOSS) with Sector Outperform Recommendation

July 14 at 2:35 PM | msn.com

Gossamer Bio (NASDAQ:GOSS) Now Covered by Analysts at Scotiabank

July 14 at 9:04 AM | marketbeat.com

Gossamer Bio (NASDAQ:GOSS) Shares Down 3.2% - Time to Sell?

July 3, 2025 | marketbeat.com

GOSS | Gossamer Bio Inc. Annual Income Statement - MarketWatch

June 26, 2025 | marketwatch.com

Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib

June 24, 2025 | msn.com

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

June 16, 2025 | businesswire.com

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | businesswire.com

Earnings call transcript: Gossamer Bio exceeds Q1 2025 revenue forecasts

May 17, 2025 | uk.investing.com

Cantor Fitzgerald maintains Overweight on Gossamer Bio stock

May 17, 2025 | uk.investing.com

GOSSAMER BIO Earnings Results: $GOSS Reports Quarterly Earnings

May 17, 2025 | nasdaq.com

Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

Q1 2025 Gossamer Bio Inc Earnings Call

May 16, 2025 | finance.yahoo.com

Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ...

May 16, 2025 | finance.yahoo.com

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates

May 15, 2025 | zacks.com

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 15, 2025 | businesswire.com

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

May 7, 2025 | finance.yahoo.com

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2025 | businesswire.com

Gossamer Bio: Initiating Hold As Late‐Stage Data Nears Inflection

May 2, 2025 | seekingalpha.com

Pleasing Signs As A Number Of Insiders Buy Gossamer Bio Stock

April 22, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS, ARCT, BNTC, and GOSS Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$1.48 +0.10 (+7.25%)

Closing price 04:00 PM Eastern

Extended Trading

$1.52 +0.03 (+2.36%)

As of 07:03 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Arcturus Therapeutics NASDAQ:ARCT

$13.54 +0.69 (+5.37%)

Closing price 04:00 PM Eastern

Extended Trading

$13.68 +0.14 (+1.00%)

As of 06:46 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Benitec Biopharma NASDAQ:BNTC

$11.74 -0.01 (-0.09%)

Closing price 04:00 PM Eastern

Extended Trading

$11.71 -0.03 (-0.26%)

As of 06:25 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Gossamer Bio NASDAQ:GOSS

$1.71 +0.05 (+3.01%)

Closing price 04:00 PM Eastern

Extended Trading

$1.74 +0.03 (+1.75%)

As of 07:24 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time